Pharmaceutical Composition Combining PEA and CDP-Choline for Neuroprotection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative disorders associated with traumatic or vascular events and aging fail to adequately control neuroinflammation and oxidative stress, leading to significant cerebral damage and neurodegeneration.
Innovation Solution
A pharmaceutical composition combining micronized or ultramicronized palmitoylethanolamide with Cytidine-diphosphocholine, optionally co-micronized with antioxidant molecules like polyphenols, to synergistically reduce neuroinflammation and oxidative stress, thereby protecting against cerebral damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for neurodegenerative disorders, then treatment is provided, but neuroinflammation and oxidative stress are not adequately controlled, leading to significant cerebral damage
Solution Approach 1:
The patent combines two distinct therapeutic agents - palmitoylethanolamide (for neuroinflammation control) and cytidine-diphosphocholine (for membrane phospholipid synthesis and neuroprotection) - into a single pharmaceutical composition. This merging of multiple mechanisms of action into one treatment addresses the inadequacy of current single-agent therapies in simultaneously controlling neuroinflammation and preventing cerebral damage.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation containing multiple active ingredients with complementary mechanisms of action. The composition integrates anti-inflammatory, antioxidant, and neuroprotective components that work synergistically to provide comprehensive protection against neurodegenerative processes that current monotherapies fail to address.
2Reliability
If palmitoylethanolamide is administered to control neuroinflammation, then neuroinflammation is controlled, but the synergic effect with other molecules is not fully utilized
Solution Approach 1:
The patent merges palmitoylethanolamide with cytidine-diphosphocholine in a single pharmaceutical composition to create a synergic therapeutic effect. The combination leverages the anti-inflammatory properties of PEA while simultaneously utilizing the membrane-stabilizing and neuroprotective effects of CDP-choline, thereby enhancing overall therapeutic efficiency beyond what either agent could achieve alone.
3Ease of operation
If micronized or ultramicronized forms of palmitoylethanolamide are used, then bioavailability is improved, but the synergic association with cytidine-diphosphocholine is not fully realized
Solution Approach 1:
The patent combines micronized or ultramicronized palmitoylethanolamide (optimized for bioavailability) with cytidine-diphosphocholine in a single pharmaceutical composition. This merging ensures that the improved absorption characteristics of the micronized form are coupled with the neuroprotective effects of CDP-choline, thereby realizing both enhanced bioavailability and full synergic therapeutic effect.
Data Source
Figure 1A~1B
Figure 2
AI summary
The object of the present invention is a pharmaceutical composition for use in humans or animals containing N-palmitoylethanolamide and Cytidine-diphosphocholine for the treatment of pathologies of the Central Nervous System of a traumatic, vascular, degenerative nature associated with neurodegeneration. In particular, the present invention concerns a pharmaceutical composition comprising palmitoylethanolamide (PEA) and Cytidine-diphosphocholine (CDP-Choline or Citicoline), possibly with the addition of an antioxidant compound such as for example a polyphenol, alpha-lipoic acid or L-acetylcysteine.